<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322513</url>
  </required_header>
  <id_info>
    <org_study_id>covid-19 biomarkers</org_study_id>
    <nct_id>NCT04322513</nct_id>
  </id_info>
  <brief_title>Biomarkers for Identification of COVID-19 Infection</brief_title>
  <acronym>B-DT-COV2</acronym>
  <official_title>Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Pugliese Ciaccio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Policlinico &quot;Mater Domini&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Catanzaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lung injury represents the most severe form of the viral infection sustained by
      coronavirus disease 2019 (Covid-19) also named as SARS-CoV-2, a new virus emerged in December
      2019 in Wuhan (China). The diagnosis is clinical and patients develop flu-like syndrome with
      fever and cough; patients with clinical symptoms can perform a swab test for diagnosis of
      positivity to Covid-19. Even if diagnosis and treatment are well described, to date, this
      viral pandemic infection induces an increased mortality in the world. The aim of the present
      project is to evaluate specific biomarkers that could be used for patient stratification and
      for tailor therapy in COVID-19 infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers expression</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Change in biomarkers (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) in covid-19 positive patients vs covid-negative patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Biomarkers expression</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Change in CYP450 expression in covid-19 positive patients that develop adverse drug reactions or drug inefficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biomarkers expression (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment</measure>
    <time_frame>60 days</time_frame>
    <description>Changes in biomarkers in covid-19 patients before and after standard treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Covid-19 positive patients</arm_group_label>
    <description>all drugs used for standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Covid-19 negative patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biomarkers expression</intervention_name>
    <description>Evaluation in biomarkers expression between 2 groups</description>
    <arm_group_label>Covid-19 negative patients</arm_group_label>
    <arm_group_label>Covid-19 positive patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of both sexes and &gt; 18 years with and without covid-19 infection that came in
        hospital for flu-like syptoms: cough fever and dyspnea
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 75 years, extremes included, male or female In conscious patients,
             ability to understand and the willingness to sign a written informed consent document;
             in unconscious patients informed consent will be signed from parents or legal tutors.

        Exclusion Criteria:

          -  Patients that don't sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LUCA GALLELLI</last_name>
    <phone>3339245656</phone>
    <phone_ext>3339245656</phone_ext>
    <email>gallelli@unicz.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Luca Gallelli</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUCA GALLELLI</last_name>
      <phone>3339245656</phone>
      <phone_ext>3339245656</phone_ext>
      <email>gallelli@unicz.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

